Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Gallus BioPharmaceuticals Utilizes ambr15 Micro Bioreactor

Published: Tuesday, May 06, 2014
Last Updated: Tuesday, May 06, 2014
Bookmark and Share
To rapidly optimize process development of novel antibodies and biosimilars.

TAP Biosystems has announced that its ambr15 micro bioreactor system is being used at the leading US-based Contract Manufacturing Organization (CMO), Gallus BioPharmaceuticals, LLC (“Gallus”) to optimize process development and clone selection of novel antibody therapeutics and biosimilars.

Gallus’ scientists are using the ambr15 micro bioreactor in their new, Process Development facility in St. Louis, Missouri. The system is being used for clone selection programmes to determine which CHO cell lines are stable and produce the highest titre mAbs.

They are also using the ambr system to optimize media selection and feed strategies for these mAbs, which are being developed as antibody therapeutics and biosimilars for some of the world’s top pharma and biotech firms.

Matt Caple, Scientific Director of Cell Culture Development at Gallus said: “Our clients want high yielding, pure biotherapeutic antibodies that they can take into clinical trials as quickly as possible. However, they often come to us without any process development history for their mAb clones and we have to ensure we build them a robust process. We used to do this with multiple shake flask and benchtop scale bioreactor runs - in one media development project we performed 1000 shake flasks runs - however, we knew we couldn’t continue to work at this labour-intensive scale. So we assessed a number of bioreactor models and concluded that the ambr15 system was the right option for us.”

Caple added: “We have now been working with our ambr15 for six months and, from our comparison studies, have seen the titre results of our mAbs correlate well with those we obtained in 50L bioreactors. We are currently using ambr15 routinely for our bioprocess characterization work and are looking at using it for perfusion culture modelling. For us, ambr is ‘game changing’ technology, so much so that we are now running it around the clock and are considering buying a second system.”

Dr Barney Zoro, ambr15 Product Manager at TAP Biosystems stated: "We’re delighted that Gallus has integrated the ambr15 system so seamlessly into their new Process Development facility. Their confidence in the system shows scientists that ambr15 is the proven choice for helping to deliver robust, high-performance cell culture processes, especially where biotech and pharma clients are imposing stringent timelines and product quality targets.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck and TAP Biosystems Finalists for “Best Collaboration Award”
Recognizing ambr250 as a breakthrough technology for process development.
Wednesday, October 08, 2014
TAP and Gallus Co-host Free Webinar
Explaining the benefits of using ambr15 microbioreactors for DoE.
Wednesday, October 01, 2014
New Webinars Explore Feed Strategy Challenges Using Mini Bioreactors
Detailing how to achieve consistent feeding regimes for reproducible scale-up.
Thursday, September 25, 2014
New Webinar on Mimicking Perfusion Culture Using Micro Bioreactors
Presents validation data for improving media screening and process optimization.
Friday, February 14, 2014
TAP Biosystems Presents New Data on 3D Cell Culture Research
Discussing the application of RAFT 3D models in oncology, toxicology and neuroscience cell-based screening programmes.
Monday, January 20, 2014
TAP Biosystems Partners with Life Technologies on Protein Expression Platform
The companies will collaborate to develop a cost-efficient, high throughput protein expression platform.
Tuesday, January 15, 2013
Collaboration between TAP Biosystems and UCL to Develop Biomimetic 3D Cancer Models
TAP Biosystems announced new collaboration to develop solid tumour tissue models using its RAFT 3D cell culture system for use in drug discovery applications.
Friday, October 12, 2012
Scientific News
Lung Repair and Regeneration Gene Discovered
New role for hedgehog gene offers better understanding of lung disease.
How Cell Growth Triggers Cell Division
Researchers in Jan Skotheim's lab have discovered a previously unknown mechanism that controls how large cells grow, an insight that could one day provide insight into attacking diseases such as cancer.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Probing the Forces Involved in Creating The Mitotic Spindle
Scientists at The Rockefeller University reveal new insights into the mechanical forces that govern elements of the mitotic spindle formation.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos